Overview
A Study to Investigate the Tolerability, Safety,Pharmacokinetics and efficacy of GR1603 in subjects with Systemic Lupus Erythematosus ； GR1603 injection is a monoclonal antibody targeting IFNAR1, which can block IFNAR binding to type I interferons such as IFNα and be used to treat systemic lupus erythematosus.
Description
This is a Phase Ib/Ⅱ,double blind, multiple-dose study to evaluate the pharmacokinetics (PK), safety，tolerability and efficacy of intravenously administered GR1603 in participants with active SLE despite receiving standard of care .
Phase Ib is a multi-dose escalation phase in which 16 subjects are scheduled to enroll.
A total of 120 subjects were randomly assigned to GR1603 injection low dose group, high dose group or placebo group in phase Ⅱ.
Eligibility
Inclusion Criteria:
- Diagnosis of SLE according to the ACR 1997 ≥24 weeks
- Active moderate to severe SLE
- At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith.
Exclusion Criteria:
- Active severe or unstable neuropsychiatric SLE
- Clinically significant laboratory test
- Clinically significant active infection